DE602007007362D1 - Radioaktiv markierte verbindungen auf peptidbasis und ihre verwendung - Google Patents

Radioaktiv markierte verbindungen auf peptidbasis und ihre verwendung

Info

Publication number
DE602007007362D1
DE602007007362D1 DE602007007362T DE602007007362T DE602007007362D1 DE 602007007362 D1 DE602007007362 D1 DE 602007007362D1 DE 602007007362 T DE602007007362 T DE 602007007362T DE 602007007362 T DE602007007362 T DE 602007007362T DE 602007007362 D1 DE602007007362 D1 DE 602007007362D1
Authority
DE
Germany
Prior art keywords
compounds
peptide base
radioactively marked
marked compounds
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007007362T
Other languages
English (en)
Inventor
Torgrim Engell
Steven Fairway
Ingrid Henriksen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
GE Healthcare AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare AS filed Critical GE Healthcare AS
Publication of DE602007007362D1 publication Critical patent/DE602007007362D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE602007007362T 2006-12-11 2007-12-11 Radioaktiv markierte verbindungen auf peptidbasis und ihre verwendung Active DE602007007362D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86938206P 2006-12-11 2006-12-11
PCT/NO2007/000434 WO2008072973A2 (en) 2006-12-11 2007-12-11 Radiolabelled peptide based compounds and uses thereof

Publications (1)

Publication Number Publication Date
DE602007007362D1 true DE602007007362D1 (de) 2010-08-05

Family

ID=39252990

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007007362T Active DE602007007362D1 (de) 2006-12-11 2007-12-11 Radioaktiv markierte verbindungen auf peptidbasis und ihre verwendung

Country Status (15)

Country Link
US (1) US20100322857A1 (de)
EP (1) EP2101826B1 (de)
JP (1) JP2010512310A (de)
KR (1) KR20090097868A (de)
CN (2) CN102321154A (de)
AT (1) ATE471724T1 (de)
AU (1) AU2007332210A1 (de)
BR (1) BRPI0720257A2 (de)
CA (1) CA2671564A1 (de)
DE (1) DE602007007362D1 (de)
ES (1) ES2346595T3 (de)
MX (1) MX2009006028A (de)
PL (1) PL2101826T3 (de)
RU (1) RU2009119917A (de)
WO (1) WO2008072973A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027584A1 (ja) * 2009-09-04 2011-03-10 国立大学法人京都大学 膵島イメージング用分子プローブ及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570493B1 (de) * 1991-02-08 2000-01-05 Diatide, Inc. Technetium-99m markierte Polypeptide zur Bildformung
NZ521735A (en) * 2000-04-12 2004-12-24 Amersham Health As Peptide-based compounds, their use as targeting vectors that bind to receptors associated with antiogenesis such as integrin receptors
RU2303042C2 (ru) * 2001-07-10 2007-07-20 Джи-И Хелткер АС Соединения на основе пептидов для направленной доставки к рецепторам интегринов
GB0116815D0 (en) * 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
NO20030115D0 (no) * 2003-01-09 2003-01-09 Amersham Health As Kontrastmiddel
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods

Also Published As

Publication number Publication date
CA2671564A1 (en) 2008-06-19
MX2009006028A (es) 2009-06-17
RU2009119917A (ru) 2011-01-20
AU2007332210A1 (en) 2008-06-19
WO2008072973A2 (en) 2008-06-19
ATE471724T1 (de) 2010-07-15
ES2346595T3 (es) 2010-10-18
WO2008072973A3 (en) 2009-05-22
JP2010512310A (ja) 2010-04-22
US20100322857A1 (en) 2010-12-23
CN101563108B (zh) 2012-07-18
EP2101826A2 (de) 2009-09-23
EP2101826B1 (de) 2010-06-23
CN102321154A (zh) 2012-01-18
KR20090097868A (ko) 2009-09-16
PL2101826T3 (pl) 2010-11-30
CN101563108A (zh) 2009-10-21
BRPI0720257A2 (pt) 2014-02-25

Similar Documents

Publication Publication Date Title
BRPI0412986A (pt) composto, método para o diagnóstico ou formação de imagem in vivo de uma doença ou condição associadas com a angiogênese, formulação radiofarmacêutica, método para a preparação de um composto, e, kit para a preparação de um peptìdeo radiofluorado
CY1119367T1 (el) Παραγοντες προσδεσης του psma και χρησεις αυτων
CY1114132T1 (el) Γαστροανθεκτικες φαρμακοτεχνικες μορφες που περιεχουν ριφαξιμινη
BRPI0515175A (pt) método para radiofluoração, composto, composição radiofarmacêutica, uso de um conjugado radiorrotulado ou um sal do mesmo, método para diagnose ou formação de imagem in vivo de uma doença ou condição associada com a angiogênese, e, método para monitorar o efeito do tratamento de um corpo humano ou animal com um medicamento para combater uma condição associada com cáncer
BRPI0210886B8 (pt) composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
ATE464579T1 (de) Bildgebende medizinische einheit
DE602004016010D1 (de) Verfahren zur ä11cü-radiomarkierung von phenthiazin und phenothiazinartige verbindungen
ATE434445T1 (de) Bei tumorbildgebung und krebsbehandlung als trägermittel für pharmazeutische verbindungen eingesetzte autoantikörper
ATE411819T1 (de) Konjugate für medizinische abbildungen umfassend träger, targeting-anteile und kontrastmittel
DE60207612D1 (de) Verbindungen zur bilddarstellung der alzheimer-krankenheit
WO2018174721A3 (en) Indicator fluids, systems, and methods for assessing movement of substances within, to or from a cerebrospinal fluid, brain or spinal cord compartment of a cranio-spinal cavity of a human
BRPI0520092A2 (pt) derivado de feniloxianilina marcado com halogênio radioativo, e, agente de diagnósitico de doença
Fani et al. Selection of the first 99mTc-labelled somatostatin receptor subtype 2 antagonist for clinical translation—Preclinical assessment of two optimized candidates
Handula et al. Towards complete tumor resection: Novel dual-modality probes for improved image-guided surgery of grpr-expressing prostate cancer
DE602007007362D1 (de) Radioaktiv markierte verbindungen auf peptidbasis und ihre verwendung
CN103998929A (zh) 选择患者的方法
NO20033115D0 (no) Peptid-baserte forbindelser
Abouzayed et al. Preclinical characterization of a stabilized gastrin-releasing peptide receptor antagonist for targeted cancer theranostics
Gawlikowska-Sroka et al. Topography of the mental foramen in human skulls originating from different time periods
of Gerontology et al. Chinese clinical practice guidelines for digital memory clinic
Qin Recent advances of injectable radiopharmaceuticals for nuclear imaging and therapy: a new era in nuclear medicine
CL2008002267A1 (es) Uso de compuestos derivados de pirinmetilsulfinilbencimadazol y piperidinilaminobencimidazol como marcadores especificos para enfermedades neurodegenerativas y patologias tau; y como metodo de diagnostico de enfermedad de alzheimer, y formulacion farmaceutica que comprende dichos compuestos marcados radiactivamente o con fluorescencia.
ATE437884T1 (de) Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
Obeid et al. GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics
Tham et al. Post-treatment follow-up of patients with nasopharyngeal cancer